Select a medication above to begin.
Zymfentra (infliximab-dyyb)
infliximab
Black Box Warnings .
Serious Infection Risk
weigh tx benefit vs. risk in patients with chronic or recurrent infection; pulmonary and extrapulmonary tuberculosis (TB), invasive fungal infections, and other opportunistic infections including Legionella and Listeria observed; some infections have been fatal; most infections occur in combo with other immunosuppressants; evaluate for TB risk factors and screen for latent TB infection before and during infliximab tx; initiate anti-TB tx before infliximab tx; monitor for infection signs/symptoms during and after infliximab tx; since active TB has developed in patients with negative tuberculin skin test, monitor all patients for active TB signs/symptoms; since histoplasmosis may be present in patients with negative antigen and antibody tests, consider empiric antifungal tx in patients with severe systemic illness if at risk for invasive fungal infection; D/C infliximab tx if serious infection or sepsis occurs
Malignancy
lymphoma and other malignancies, some fatal, reported in children and adolescents treated with TNF blockers; post-marketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) reported mostly in Crohn disease or ulcerative colitis patients, mostly adolescent and young adult males receiving concomitant azathioprine or mercaptopurine; uncertain whether HSTCL related to TNF-blocker monotherapy or in combo with other immunosuppressants
Adult Dosing .
Dosage forms: INJ (pen): 120 mg per injection; INJ (pre-filled syringe): 120 mg per mL
Special Note
- [drug name clarification]
- Info: nonproprietary name = infliximab-dyyb
Crohn disease, moderate-severe
- [conversion from infliximab IV induction tx]
- Dose: 120 mg SC q2wk; Start: at wk 10 after induction tx with IV form (5 mg/kg/dose IV x1 on wk 0, 2, 6); Info: not for initial tx
- [conversion from infliximab IV maintenance tx]
- Dose: 120 mg SC q2wk; Start: in place of next scheduled dose of IV maintenance tx; Info: not for initial tx
ulcerative colitis, moderate-severe
- [conversion from infliximab IV induction tx]
- Dose: 120 mg SC q2wk; Start: at wk 10 after induction tx with IV form (5 mg/kg/dose IV x1 on wk 0, 2, 6); Info: not for initial tx
- [conversion from infliximab IV maintenance tx]
- Dose: 120 mg SC q2wk; Start: in place of next scheduled dose of IV maintenance tx; Info: not for initial tx
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- hypersensitivity to murine protein
- infection, active
- COPD, moderate-severe
- CHF
- demyelinating disease
- myelosuppression
- myelosuppression history
- malignancy history
- caution: malignancy risk
- caution: patients >65 yo
- caution: infection risk
- caution: infection, chronic
- caution: infection, recurrent
- caution: diabetes mellitus, uncontrolled
- caution: opportunistic infection history
- caution: TB infection, latent
- caution: TB infection risk
- caution: residents of area with endemic TB
- caution: residents of area with endemic mycosis
- caution: travelers in area with endemic TB
- caution: travelers in area with endemic mycosis
- caution: HBV infection
- caution: HBV infection history
Drug Interactions .
Overview
infliximab
TNF blocker
- cardiotoxic effects
- immunomodulatory effects
- caution advised with narrow therapeutic index drugs; chronic inflammatory conditions may alter metabolic enzyme formation; tx with immune modulators may reverse this effect, resulting in altered levels of concomitant drugs
Contraindicated
- adenovirus vaccine, live
- BCG live intravesical
- chikungunya vaccine, live
- cholera vaccine, live
- dengue vaccine, live
- influenza nasal vaccine, live
- measles/mumps/rubella vaccine, live
- rotavirus vaccine, live
- smallpox vaccine, live
- talimogene laherparepvec
- typhoid vaccine, live
- varicella vaccine, live
- yellow fever vaccine, live
Avoid/Use Alternative
- abatacept
- abrocitinib
- adalimumab
- alemtuzumab
- anakinra
- anifrolumab
- baricitinib
- belimumab
- brodalumab
- canakinumab
- certolizumab pegol
- cladribine oral
- deuruxolitinib
- dupilumab
- eculizumab
- efgartigimod alfa
- epirubicin
- etanercept
- etrasimod
- golimumab
- guselkumab
- idarubicin
- infliximab
- ixekizumab
- mirikizumab
- nadofaragene firadenovec intravesical
- natalizumab
- ocrelizumab
- ofatumumab
- pimecrolimus topical
- rabies vaccine
- ravulizumab
- rilonacept
- risankizumab
- ritlecitinib
- rituximab
- ruxolitinib topical
- sarilumab
- secukinumab
- siltuximab
- spesolimab
- teplizumab
- tildrakizumab
- tocilizumab
- tofacitinib
- tralokinumab
- upadacitinib
- ustekinumab
- vedolizumab
- vilobelimab
Monitor/Modify Tx
- ado-trastuzumab emtansine
- aficamten
- aldesleukin
- alogliptin
- anagrelide
- anthrax vaccine
- asciminib
- avelumab
- axitinib
- bevacizumab
- bezlotoxumab
- binimetinib
- bortezomib
- bosutinib
- capecitabine
- carfilzomib
- chikungunya vaccine
- cilostazol
- clozapine
- cobimetinib
- COVID-19 vaccine
- cyclophosphamide
- dabrafenib
- daunorubicin
- diphtheria/tetanus vaccine
- diphtheria/tetanus/pertussis vaccine
- doxorubicin
- dronedarone
- ebola vaccine, live
- encorafenib
- entrectinib
- everolimus
- fam-trastuzumab deruxtecan
- fluorouracil
- Haemophilus b vaccine
- hepatitis A vaccine
- hepatitis B vaccine
- human papillomavirus vaccine
- hydroxychloroquine
- ibrutinib
- ifosfamide
- imatinib
- influenza H5N1 vaccine
- influenza vaccine
- interferon beta 1a
- interferon beta 1b
- interferon gamma 1b
- itraconazole
- Japanese encephalitis vaccine
- lapatinib
- lenvatinib
- linagliptin
- margetuximab
- mavacamten
- meningococcal vaccine
- mirdametinib
- mitomycin
- mitoxantrone
- mobocertinib
- osimertinib
- pazopanib
- peginterferon beta 1a
- pertuzumab
- pioglitazone
- pneumococcal vaccine
- poliovirus vaccine
- ponatinib
- propafenone
- respiratory syncytial virus vaccine
- ripretinib
- ropeginterferon alfa-2b
- rosiglitazone
- saxagliptin
- selumetinib
- sipuleucel-T
- sitagliptin
- smallpox/mpox vaccine, live
- sorafenib
- sunitinib
- tick-borne encephalitis vaccine
- tivozanib
- trabectedin
- trametinib
- trastuzumab
- typhoid vaccine
- vandetanib
- zanidatamab
- zenocutuzumab
- zongertinib
Caution Advised
- abemaciclib
- acalabrutinib
- afamitresgene autoleucel
- anti-thymocyte globulin
- atidarsagene autotemcel
- avacopan
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- basiliximab
- beclomethasone inhaled
- beclomethasone nasal
- belatacept
- belinostat
- bendamustine
- betamethasone
- bimekizumab
- blinatumomab
- brentuximab vedotin
- brexucabtagene autoleucel
- budesonide
- budesonide inhaled
- budesonide nasal
- budesonide rectal
- busulfan
- cabazitaxel
- carboplatin
- carmustine
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- clobetasol ophthalmic
- clofarabine
- coccidioides immitis skin test antigen
- copanlisib
- corticotropin
- cortisone
- crovalimab
- cyclosporine
- cytarabine
- dactinomycin
- danicopan
- daratumumab
- decitabine
- deflazacort
- delgocitinib topical
- deucravacitinib
- dexamethasone
- dexamethasone ophthalmic
- difluprednate ophthalmic
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- duvelisib
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- eribulin
- etoposide
- etuvetidigene autotemcel
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- flunisolide nasal
- fluocinolone intravitreal
- fluorometholone ophthalmic
- fluticasone furoate
- fluticasone propionate
- fruquintinib
- gemtuzumab ozogamicin
- glofitamab
- hydrocortisone
- hydrocortisone ophthalmic
- hydroxyurea
- ibritumomab tiuxetan
- icotrokinra
- idecabtagene vicleucel
- idelalisib
- inebilizumab
- inotuzumab ozogamicin
- iptacopan
- irinotecan
- isatuximab
- ixabepilone
- lebrikizumab
- leflunomide
- lenalidomide
- lifileucel
- linvoseltamab
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- loteprednol ophthalmic
- lymphocyte immune globulin, anti-thymocyte globulin
- melphalan
- mercaptopurine
- methotrexate
- methylprednisolone
- mogamulizumab
- momelotinib
- mometasone implant
- mometasone inhaled
- mometasone nasal
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- narsoplimab
- nelarabine
- nipocalimab
- obecabtagene autoleucel
- obinutuzumab
- oxaliplatin
- ozanimod
- paclitaxel
- pegcetacoplan
- pentostatin
- pirtobrutinib
- polatuzumab vedotin
- pomalidomide
- ponesimod
- pozelimab
- prednisolone
- prednisolone ophthalmic
- prednisone
- procarbazine
- quizartinib
- regorafenib
- rilzabrutinib
- romidepsin
- rozanolixizumab
- ruxolitinib
- satralizumab
- selinexor
- sibeprenlimab
- siponimod
- sirolimus
- sirolimus albumin-bound
- sulfasalazine
- sutimlimab
- tacrolimus
- tafasitamab
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- temsirolimus
- teriflunomide
- thioguanine
- thiotepa
- tisagenlecleucel
- topotecan
- triamcinolone
- tuberculin purified protein derivative
- ublituximab
- vamorolone
- venetoclax
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanubrutinib
- zilucoplan
Adverse Reactions .
Serious Reactions
- infection, serious
- opportunistic infection
- tuberculosis
- HBV reactivation
- malignancy
- lymphoma
- leukemia
- skin CA
- cervical CA
- myelosuppression
- hypersensitivity reaction
- anaphylaxis
- serum sickness
- toxic epidermal necrolysis
- Stevens-Johnson syndrome
- MI
- arrhythmia
- CHF
- CVA
- neurologic disorders
- optic neuritis
- lupus-like syndrome
- vasculitis
- sarcoidosis
- interstitial lung disease
- hepatotoxicity
Common Reactions
- URI
- headache
- injection site reaction
- anemia
- diarrhea
- CPK incr.
- arthralgia
- ALT incr.
- abdominal pain
- HTN
- UTI
- neutropenia
- dizziness
- leukopenia
- infection, serious
Safety/Monitoring .
Monitoring Parameters
hepatitis B serology including HBsAg at baseline; TB test at baseline, then periodically; LFTs, including ALT/AST, q3-4mo; active TB signs/symptoms; dermatologic exams, especially if incr. skin CA risk
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; inadequate human data available with SC route, though no known risk of teratogenicity based on human data with IV route; possible risk of neonatal agranulocytosis based on limited human data with IV route; possible risk of neonatal immunosuppression based on drug's mechanism of action; for infants exposed to infliximab in utero, avoid live vaccines for at least 6mo after birth
Lactation
Clinical Summary
may use while breastfeeding; no human data available with SC route, though no known risk of infant harm based on limited human data with IV route and drug properties; no human data available to assess effects on milk production
Pharmacology .
Metabolism: for infliximab: proteolytic degradation; CYP450: unknown
Excretion: for infliximab: unknown; Half-life: 13.8 days
Subclass: Inflammatory Bowel Disease (IBD)
Mechanism of Action
for infliximab: binds and inhibits tumor necrosis factor alpha, reducing inflammation and altering immune response
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.